Literature DB >> 4051322

Responses to large doses of salbutamol and theophylline in patients with chronic obstructive pulmonary disease.

R B Filuk, P A Easton, N R Anthonisen.   

Abstract

To assess additive effects of therapy with salbutamol and theophylline, we examined 16 patients (5 women, 11 men) with a mean age of 67.6 +/- 6.9 (SE) yr, long-standing chronic obstructive pulmonary disease, an FEV1 of 0.73 +/- 0.05 (SE) L, and a smoking history of 38.4 +/- 4.1 (SE) pack-years. On 2 consecutive days they were given large doses of either salbutamol followed by theophylline or vice versa. In the group as a whole, responses to salbutamol alone averaged 24% of the baseline FEV1 and responses to theophylline alone were 17% of baseline. Similar increases were observed when either drug was given after the other; responses to the 2 agents were additive. Responses to salbutamol were larger (p less than 0.05) than those to theophylline. Responses to salbutamol and theophylline were correlated. In 8 patients whose FEV1 increased after salbutamol by more than both 20% and 0.2 L, adding theophylline produced responses that were also large (32% baseline and 0.22 L). In the remaining 8 nonresponsive patients, salbutamol and theophylline were also additive, but the small (mean 10% or 0.06 L) increases in FEV1 with theophylline raised the question of the risk benefit ratio of high-dose theophylline therapy in such patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4051322     DOI: 10.1164/arrd.1985.132.4.871

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

1.  Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease.

Authors:  A Ikeda; K Nishimura; H Koyama; M Tsukino; M Mishima; T Izumi
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

Review 2.  Risk/benefit ratio of long-term treatment with beta 2-adrenoceptor agonists.

Authors:  I Ziment
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 3.  Management of asthma and chronic airflow limitation: are methylxanthines obsolete?

Authors:  M T Newhouse; A Lam
Journal:  Lung       Date:  1990       Impact factor: 2.584

4.  Differences in utilisation of asthma drugs between two neighbouring Swedish provinces: relation to prevalence of obstructive airway disease.

Authors:  L Larsson; G Boëthius; M Uddenfeldt
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

5.  What role for theophylline?

Authors:  J W Jenne
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

Review 6.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 7.  Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  A Ikeda; K Nishimura; T Izumi
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

Review 8.  Chronic obstructive pulmonary disease.

Authors:  N R Anthonisen
Journal:  CMAJ       Date:  1988-03-15       Impact factor: 8.262

9.  Bronchodilator effect and serum theophylline level after combined treatment with fenoterol and theophylline in reversible chronic airflow obstruction.

Authors:  M I Lucena; J Almagro; F Rius; F Sanchez de la Cuesta
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Guidelines for the assessment and management of chronic obstructive pulmonary disease. Canadian Thoracic Society Workshop Group.

Authors: 
Journal:  CMAJ       Date:  1992-08-15       Impact factor: 8.262

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.